Raul D Santos 1,2 and Viviane Z Rocha 1 Atherosclerosis is a ubiquitous multifactorial chronic degenerative disease in which pro-atherogenic lipoproteins and inflammation play complementary roles. 1, 2 Currently there is consensus that not only cholesterol but also inflammation need to be reduced to prevent cardiovascular events adequately. 2 The causal role of inflammation in atherosclerotic cardiovascular disease (ASCVD) has been robustly demonstrated in experimental, observational, Mendelian randomisation and interventional studies. [2] [3] [4] [5] [6] [7] [8] [9] [10] Among different pathways that regulate inflammation, interleukin-6 (IL-6) and its effector mechanisms play a pivotal role. 3, 5, 6, 9, 11 Indeed, there is evidence from CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) that inhibition of interleukin-1b with downstream IL-6 signalling modulation prevents ASCVD events. 8 IL-6 physiology is rather complex as this cytokine may influence the inflammatory cascade by two distinctive and independent pathways: the classic IL-6 signalling and IL-6 trans-signalling. 11 In the former, IL-6 binds to its specific receptor (IL-6R) which is associated with a protein unit called gp130 in a few cell types such as hepatocytes, lymphoid cells and megakaryocytes. This leads to the synthesis of acute phase proteins such as plasminogen activator inhibitor (PAI-1), C-reactive protein (CRP), fibrinogen and serum amyloid A protein (SAA), mainly by the liver. 11 In addition, IL-6 may also bind to a soluble form of its receptor in the plasma called sIL-6R, and the binding of this binary complex to the gp130 expressed in different cell types leads to extra pro-inflammatory responses. This process, called IL-6 trans-signalling, is tightly regulated, being inactivated by a ternary complex formed when the duo IL-6 and sIL-6R binds to the soluble form of the gp130 protein (sgp130). 9 This ternary complex (IL-6:sIL-6R:sgp130) cannot bind to cell gp130 and therefore it does not induce tissue inflammation. The magnitude of IL-6 trans-signalling can be estimated by the ratio of pro-inflammatory binary/neutralising ternary (B/T) complexes, the higher the ratio the greater the intensity and vice-versa 9 (Figure 1 ).
Despite its elevated frequency, the course of ASCVD manifestations is variable and risk stratification is essential for the establishment of adequate pharmacological preventive strategies in addition to perpetually recommended 'healthy lifestyles'. 12 In addition to risk equations that encompass classic parameters such as age, blood pressure, lipids and smoking, many other biomarkers have been tested in robust clinical studies in order to improve risk stratification. Considering the pivotal role played by inflammation in atherosclerosis development, some biomarkers, such as CRP and IL-6 and its pathways, have been tested with the purpose of discriminating and reclassifying risk. [4] [5] [6] 11 CRP is an inflammatory biomarker that independently predicts ASCVD risk in both primary and secondary prevention individuals, ensuring its place in clinical practice. Indeed, CRP can be used not only as an indicator for low-density lipoprotein (LDL) cholesterol lowering, 4,10,13,14 but also to start anti-inflammatory therapy with the aim of reducing cardiovascular events as shown in the CANTOS study. 7, 8 But what about IL-6? Is there enough information allowing the physician to incorporate this biomarker in preventive cardiology clinical practice? IL-6 can exert its proatherogenic properties by acting through either the classic signalling pathway leading to elevation of circulating CRP and other acute phase reactants, or through trans-signalling, a mechanism in which CRP is not involved. 5, 6, 9, 11 Indeed, there is very recent evidence showing that the evaluation of the IL-6 trans-signalling pathway may help discriminate and reclassify ASCVD risk in middle-aged primary prevention individuals as has been shown by Ziegler et al. 9 In this issue of the journal the same authors expand and test their previous findings according to LDL-cholesterol values and the estimated Framingham risk score (FRS) in 4232 middle-aged Swedish individuals (60YO cohort) without previous manifestations of ASCVD. 15 The intensity of IL-6 trans-signalling was estimated by the B/T complex ratio as previously described. 9 After a median 16.5year follow-up, 15% of studied subjects presented one cardiovascular event (n ¼ 525). After multivariate adjustment those with B/T ratios greater than the median (high B/T ratio) had greater hazards for total cardiovascular events, with an apparent stronger association for those with LDL-cholesterol less than 4 mmol/L than those with higher LDL-cholesterol concentrations; hazard ratios (HRs) of, respectively, 1.59 (95% confidence interval (CI) 1.24-2.05) and 1.29 (95% CI 1.00-1.67). Similar trends were encountered for either coronary or stroke events. Of interest, a high B/T ratio was also associated with an earlier onset of cardiovascular events (3-4 years earlier) especially ischaemic stroke in those with LDL-cholesterol less than 4 mmol/L. When individuals were separated according to the overall calculated ASCVD risk of 10% or less and over 10% to 20% or less the HR for a high R/T ratio was, respectively, 1.27 (95% CI 1.00-1.61) and 1.78 (95% CI 1.36-2.34). No association with risk was encountered for those with a calculated FRS greater than 20%. No interaction was encountered between LDL-cholesterol and a high B/T complex ratio with either biomarker associated independently with ASCVD risk. The addition of the B/T ratio as a categorical value (greater than or less than the median) to a risk model including FRS and IL-6 concentrations provided a reasonable discriminatory value for the whole study population (area under the receiver operating characteristic (ROC) curve -area under the curve (AUC) 0.67, 95% CI 0.64-0.70) that tended to be a little better for those with LDL-cholesterol less than 4 mmol/L (AUC 0.68, 95% CI 0.64-0.71) relative to those with LDL-cholesterol greater than 4 mmol/L (AUC 0.65, 95% CI 0.61-0.69).
The current 15 and previous observations 9 of Ziegler et al. add important information about the participation of IL-6 in ASCVD, and suggest that measurement of this cytokine pathway can give prognostic information. Despite the fact that CRP levels were not measured, the incorporation of B/T to a model including IL-6 levels, which modulates the classic signaling pathway, suggests that trans-signalling brings additional discriminatory information to the latter.
As previously shown for other biomarkers 16, 17 the B/T ratio provided greater discriminatory power for individuals classified in lower risk categories, e.g. lower LDL-cholesterol concentrations and lower calculated 10-year risk according to the FRS. This suggests that the use of these biomarkers may suit intermediate risk individuals when other risk factors act less intensively. Unfortunately, possibly because of the limited sample size, Ziegler et al. were not able to calculate the net reclassification improvement (NRI) for these risk categories as they had previously done for the Figure 1 . IL-6 signalling may occur through a classic mechanism involving IL-6 binding to IL-6 receptor expressed by a few cell types; and also through trans-signalling, which involves binding of IL-6 þ sIL-6R to gp130 expressed by several other cell types. Transsignalling is regulated by a neutralising ternary complex (IL-6 þ sIL-6R þ sgp130), and the ratio between the binary and ternary complexes associates with increased cardiovascular risk and improves the discriminatory capacity of the Framingham risk score among low to intermediate risk individuals. IL-1: interleukin-1; IL-6: interleukin-6; IL-6R: interleukin receptor; sIL-6R: soluble interleukin receptor; gp130: gp130 protein; sgp130: soluble gp130 protein; CRP: C-reactive protein; PAI-1: plasminogen activator inhibitor; TNF: tumour necrosis factor.
whole study sample. 9 The NRI is a more sensitive method than C statistics to test the influence of a biomarker on risk estimation. 12 Indeed, in the same population the addition of the B/T complex ratio to a model including FRS þ IL-6 concentrations provided a 10% NRI in comparison with the latter model alone.
The study needs to be replicated in populations of other age categories and ethnicities and also in bigger sample sizes in order to prove its value as a reliable biomarker for clinical preventive cardiology practice. The study is also limited by the fact that IL-6 transsignalling was determined only once. Finally, the possible elevated costs of the B/T complex determination should be considered as a barrier for its implementation in preventive cardiology practice. At any rate the studies of Ziegler et al. 9, 15 add important confirmatory information for the participation of IL-6 on atherogenesis. Whether specific inhibitors of IL-6 trans-signalling 18 may reduce ASCVD events and could add to benefits shown by upstream interleukin-1b inhibition as shown in CANTOS 8 remains to be determined.
